Skip to main content
StemCell Longevita

Comparing offers

How to compare MSC sources: cord tissue, bone marrow and adipose

Wharton's jelly, bone marrow and fat all yield mesenchymal stromal cells, but they differ in donor age, yield, procedure burden and how they behave in culture.

Medically reviewed by:
Prof. Dr. Erdal Karaöz Team
Last reviewed:
Next review:

The short answer

The honest comparison is about trade-offs, not a winner. Autologous bone marrow and adipose avoid donor-matching questions but require a harvest procedure and decline in yield and proliferative capacity with donor age. Allogeneic Wharton's jelly MSCs come from a young, ethically donated tissue with high yield and no harvest procedure for you, but require donor screening, a licensed tissue establishment and, in most frameworks, a stricter regulatory pathway. Ask which source, why that source for your indication, and what the screening looks like.

How to weigh the sources

These steps work at any clinic, anywhere. Nothing here depends on choosing us.

  1. Ask which tissue the cells come from and whether the product is autologous (yours) or allogeneic (a donor's).
  2. If autologous, ask about the harvest: which procedure, what anaesthesia, what recovery, and what yield is expected at your age.
  3. If allogeneic, ask about donor consent, serological screening, and the tissue establishment licence behind the donation.
  4. Ask whether the cells are expanded in culture and for how many passages, since late-passage cells lose potency.
  5. Ask what culture supplements are used — human platelet lysate versus fetal bovine serum matters for both immunogenicity and for patients who object to animal products.
  6. Ask for the evidence specific to that source in your indication, not to MSCs in general.

What good looks like, and what should worry you

Verification signals for Compare MSC sources
What you are checkingAn acceptable answerA red flag
Source namedSpecific tissue and autologous/allogeneic status'Stem cells' with no origin
CharacterisationISCT marker panel confirms MSC identityNo marker data
Donor screeningConsent and serology described for allogeneicDonor origin unexplained
Passage numberStated, and lowUnknown passage history
Culture mediaSupplement disclosed, xeno-free where claimed'Proprietary' with no detail
Indication fitSource justified for your conditionSame product sold for everything

How we grade claims like these: How we evaluate evidence · Editorial standards · Conflict-of-interest disclosure.

Documents to request in writing

Ask by email so the answer is documented. A clinic that cannot send these before payment is telling you something.

  • The tissue source and autologous/allogeneic status in writing
  • The ISCT marker panel for the batch
  • Donor screening summary for allogeneic products
  • Passage number and culture supplement used

Do not write it yourself: copy our ready-made email and WhatsApp request.

Frequently asked questions

Cord-derived MSCs generally show higher proliferative capacity and yield than adult marrow or adipose MSCs in laboratory comparisons, particularly against older donors. Whether that translates into better clinical outcomes in a given condition is far less settled, and should not be presented as proven.

It removes donor-matching and donor-screening questions but adds a harvest procedure with its own risks, and yield falls with age and comorbidity. 'Safer' depends on the patient in front of you.

Standard practice for MSC administration does not use immunosuppression, as MSCs display low HLA class II expression. This is not the same as saying an immune response is impossible, and repeat dosing is one of the areas still under study.

Allogeneic Wharton's jelly MSCs for most protocols, with the characterisation and screening documentation shared before treatment. Where another source suits the indication better, we say so.

Sources

  1. Dominici et al. Minimal criteria for defining multipotent mesenchymal stromal cells (ISCT position statement)
  2. Wharton's jelly versus bone marrow versus adipose mesenchymal stromal cells comparison proliferation — Head-to-head source comparisons.
  3. mesenchymal stromal cells donor age proliferative capacity senescence — Donor-age effects.
  4. EMA — Advanced therapy medicinal products: overview

Related verification guides

Use this on us too

Send these questions to us exactly as written. We answer them with documents, and if something does not apply to your case we say so.

Ask for the documentation · Back to the verification hub

Related pages